From Biological Complexity to Better R&D Decisions.
Tangramed helps biopharma teams make better target, indication, combination and asset decisions before costly development steps.
For investment and corporate venture teams, Tangramed provides scientific and translational diligence to pressure-test therapeutic opportunities.
Too many targets
Many targets may be biologically plausible, but only a few deserve focused investment.
Complex diseases create too many plausible options.
Multiple potential indications
A promising asset may fit several indications, treatment settings or expansion paths.
Uncertain combinations
Target pairs and drug combinations require defensible biological and translational rationale.
High-cost development decisions
Capital-intensive decisions require clear evidence, assumptions and next-step logic.
Two platform capabilities. One development framework.
Tangramed’s platform combines PleoBot™, an internally developed AI-assisted network-pharmacology engine, and Patient Avatar Cohort (PAC), a patient-derived robustness-testing capability. Integral Therapy Design (ITD) uses both to design, optimize and benchmark rational Multimodal Therapy programs, starting with ALS.
AI-assisted prioritization of targets, indications, combinations and Multimodal Therapy concepts.
PleoBotâ„¢
 Patient Avatar Cohort (PAC)
Patient-derived robustness testing across biological diversity.
Development framework using PleoBotâ„¢ and PAC to build executable Multimodal Therapy programs.
Integral Therapy Design (ITD)
PleoBotâ„¢
+
PAC
ITD
One platform, multiple strategic decisions.
From complex disease biology to actionable therapeutic decisions, our platform is designed for the unique needs of pharma, biotech, and investment teams.
Pharma & Biotech R&D teams
Prioritize targets, position assets, identify combinations and define evidence-backed next steps across discovery, preclinical and clinical development.
Business Development & Innovation
Assess external opportunities, in-licensing candidates, platform fit and differentiation before committing resources.
Investment Teams & Corporate Venture
Pressure-test whether a therapeutic asset, target, indication, combination or platform is scientifically and translationally credible before larger investment decisions.
What we help partners decide.
01. Target & pathway prioritization
Rank disease-relevant targets and pathways using multi-omics, disease networks and clinical-development evidence.
03. Target-combination discovery
Identify and rank target pairs or groups for bispecific, multispecific and other target-based therapeutic approaches.
02. Indication positioning & asset repurposing
Identify the most credible indication, expansion opportunity or repurposing path for a target, molecule or biologic.
04. Multimodal Therapy discovery & design
Identify and combine complementary therapeutic components into a coherent, testable Multimodal Therapy concept with biological rationale and a recommended validation strategy.
Decision Support Across the R&D Value Chain
Preclinical Asset
Select the most credible first indication and build the biological differentiation story.
Clinical-Stage Asset
Prioritize expansion indications, treatment settings and combination strategies.
Target Portfolio
Rank targets by disease relevance, translational evidence, druggability context and strategic fit.
Bispecific / Multispecific Program
Identify target pairs with complementary biology, relevant expression and defensible clinical rationale.
Standard-of-Care Add-on
Identify potential synergistic companions that may strengthen efficacy, broaden biological coverage or improve differentiation.
Program Reassessment / Post-No-Go
Determine whether an asset should be stopped, repositioned, combined or redirected to another indication.
External Innovation / Licensing
Rapidly assess the biological, translational and strategic fit of an in-licensing or acquisition opportunity.
Complex Disease Program
Design a multimodal therapeutic concept when single-target strategies are unlikely to control disease biology.
Investment Diligence
Help investment teams assess whether a therapeutic asset, target, indication or platform is scientifically and translationally credible.
From AI prioritization to robustness-tested therapy concepts.
Multi-omics, disease networks, pathways, interactions and clinical-development evidence.
Integrate
PleoBotâ„¢ ranks targets, indications and combinations with expert scientific curation.
Prioritize
Design
Outputs support Go / Optimize / No-Go decisions and recommended validation strategies.
Decide
Selected concepts are structured into rational Multimodal Therapy hypotheses.
Building rational Multimodal Therapy assets.
Tangramed applies its platform to create proprietary and selected partner-funded Multimodal Therapy programs in complex diseases where single-target approaches often fail.
ITD for ALS
Tangramed’s first flagship application applies Integral Therapy Design and Patient Avatar Cohort testing to amyotrophic lateral sclerosis, a highly heterogeneous neurodegenerative disease and a strong stress-test indication for multimodal therapy engineering.
Experience from discovery to clinic.
19 years of team experience in network pharmacology and multimodal therapy development
Deep expertise in rational Multimodal Therapy design and biological systems engineering.
Discovery to clinic
Experience across discovery, preclinical research, clinical development, regulatory strategy, CMC and financing.
Multimodal therapy precedent
The team previously generated and advanced PXT3003, a clinically advanced Multimodal Therapy for CMT1A.
Partner-funded collaborations
Signed AI-service collaborations in oncology and neurodegeneration, subject to approved partner wording.
Human expert curation
AI-assisted outputs are interpreted by Tangramed scientists and development experts.
Translational decision focus
Projects deliver ranked outputs, biological rationale, limitations and recommended next steps.
Non-confidential materials.
Strategic Partners
